Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

HMA-Venetoclax Beats Chemo in AML but Not for Everyone: Amir Fathi, MD

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ajmc.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

The PARADIGM trial shows the combination of hypomethylating agents with venetoclax improves remission rates in older AML patients compared to chemotherapy, but the data excludes key genetic subtypes where targeted or transplant-sparing therapies are preferred.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

New AML treatment data narrows patient groups well served by HMA-venetoclax, making precise genetic testing vital before treatment decisions. You need to integrate mutation screening to avoid costly missteps and capture the right patients for newer therapies.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechamlvenetoclaxhypomethylating-agentsclinical-trialtargeted-therapy